AGT and Alzheimer disease: The primary exposure was cumulative angiotensin II PYs, and the secondary exposure was long-term use (≥15 years).<h4>Main outcomes and measures</h4>Neuropathology outcomes were classified as Alzheimer disease related, vascular brain injury, or other.